CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 9,798 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 9,798 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total value of $517,334.40. Following the sale, the chief executive officer owned 235,558 shares of the company’s stock, valued at approximately $12,437,462.40. This represents a 3.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Thursday, February 19th, Samarth Kulkarni sold 6,967 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $52.58, for a total transaction of $366,324.86.
• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total transaction of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Stock Down 1.4%

Shares of CRSP traded down $0.67 on Friday, hitting $48.20. 1,177,562 shares of the stock traded hands, compared to its average volume of 1,978,837. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The stock’s 50 day moving average is $54.20 and its two-hundred day moving average is $57.28. The firm has a market capitalization of $4.63 billion, a P/E ratio of -7.37 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. During the same quarter last year, the firm posted ($1.01) earnings per share. The company’s revenue was down 97.8% on a year-over-year basis. Research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CRSP shares. Evercore reiterated an “outperform” rating and set a $74.00 price objective on shares of CRISPR Therapeutics in a report on Friday, February 13th. Needham & Company LLC upped their price target on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Citigroup reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, February 16th. TD Cowen upped their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $33.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $64.24.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY‑2025 commercial progress: CRSP reported $116M in FY‑25 revenue driven by CASGEVY, with $54M in Q4, supporting longer‑term revenue potential. CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth
• Positive Sentiment: Institutional buying noted: Coverage flagged that ARK Invest bought CRSP shares, signaling institutional interest that can provide buying support despite volatility. CRISPR Therapeutics (CRSP) Stock Plunges 10% as Cathie Wood’s ARK Invest Scoops Up Shares
• Positive Sentiment: Analyst tweaks modestly constructive: Brookline Capital’s updates include small upward revisions to near‑term FY2026/FY2027 EPS (less negative), which slightly improves the near‑term earnings outlook (changes are minor).
• Neutral Sentiment: Retail/investor attention rose: Zacks/Yahoo flagged CRSP among most‑searched stocks, indicating higher retail interest that can amplify moves but is not a directional signal by itself. Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
• Neutral Sentiment: Short‑interest reporting appears noisy: recent short‑interest entries in feeds show inconsistent/zero values (likely data artifacts) — not a clear signal on positioning.
• Negative Sentiment: Convertible note offering: CRISPR priced an upsized $550M convertible senior notes offering due 2031. Markets often react negatively to large convertible financings because of potential dilution and share supply; that offering coincided with sharp intraday weakness. CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
• Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales of shares (~9,798 and 2,800 shares, respectively), which can be perceived as a near‑term negative signal for sentiment. Insider Sales by CEO Samarth Kulkarni
• Negative Sentiment: Recent sharp intraday declines: media coverage noted multi‑percent drops in recent sessions after the financing news, amplifying volatility and likely contributing to continued selling pressure. CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market

Institutional Trading of CRISPR Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its holdings in CRISPR Therapeutics by 28.2% in the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock valued at $4,856,000 after purchasing an additional 31,392 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of CRISPR Therapeutics during the first quarter worth about $861,000. Woodline Partners LP boosted its position in shares of CRISPR Therapeutics by 34.3% in the first quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock worth $4,645,000 after buying an additional 34,883 shares during the period. Bank of New York Mellon Corp grew its stake in shares of CRISPR Therapeutics by 288.6% in the second quarter. Bank of New York Mellon Corp now owns 301,959 shares of the company’s stock valued at $14,687,000 after buying an additional 224,257 shares in the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at about $33,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.